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Conclusion: By changing the treatment modality from 
tomotherapy to fixed-beam IMRT, we could reduce the liver 
dose and the probability of RIHT without scarifying the target 
coverage, especially in patients whose liver dose is high. 
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Purpose or Objective: Gliomas are the most common brain 
tumor in adult patients and radiotherapy plays an important 
role in the treatment. Nonetheless, the clinical outcome for 
these patients remains poor, due to early local failure, 
suggesting the need for higher tumor doses. This study 
investigates the feasibility of dose escalating an amino acid 
18F-fluoro-ethyl-tyrosine (FET) PET defined biological target 
volume (BTV) in glioma patients by IMRT, VMAT and IMPT. 
 
Material and Methods: Seven patients were eligible for this 
study. All patients received a pre therapeutic FET-PET/CT 
and MRI. To compare, standard IMRT treatment plans giving 
60 Gy in 30 fractions to the BTV and 46 Gy to the CTV(46 Gy) 
were calculated. CTV(46 Gy) was defined as tumor and/or 
tumor cavity plus 2 cm. The BTV was generated from the FET 
PET image and covered a tumor-to-brain cut-off ratio of FET 
uptake ≥ 1.6 (pre-surgery) ≥ 2.1 (post-surgery). Both BTV and 
CTV(46 Gy) were checked visually and adapted to anatomic 
barriers. Planning target volumes, PTV boost and PTV(46 Gy) 
were generated by adding 3 mm uniformly to the BTV and 
CTV(46 Gy), respectively. The standard IMRT plans were used 
to define the base level of dose to the organs at risk (OAR) 
and PTV(46 Gy) homogeneity. To evaluate the dose to the 
OAR the mean OAR was used and the PTV(46 Gy) 
homogeneity was defined as the volume of PTV(46 Gy) 
subtracted PTV boost which received 107% of the prescribed 
46 Gy. Then, IMRT, VMAT and IMPT dose escalating treatment 
plans were calculated in order to get the highest achievable 
mean PTV boost dose, without increasing the mean dose to 
critical OAR and without decreasing the PTV(46 Gy) 
homogeneity. For all plans the dose boost was given as the 
integrated boost over 30 fractions. All treatment plans were 
carried out using the Eclipse treatment planning system 
(Varian Medical systems, Palo Alto, CA, USA). 
 
Results: A standard IMRT plans were calculated for all 
patients and the base level for PTV(46 Gy) homogeneity was 
found to range between 65 % to 86 %, with a median value of 
77%. Dose escalating, while maintaining this homogeneity, 
was found feasible using all three techniques. The obtainable 
mean and maximum doses were respective 77.1 Gy and 82.5 
Gy for IMRT, 79.2 Gy and 87.4 Gy for VMAT and 85.1 Gy and 
89.9 Gy for IMPT. On top of the significant increase in mean 
and maximum PTV boost dose obtained for IMPT, the PTV(46 
Gy) homogeneity can be decreased to a median value of 
30.4%.  
 
Conclusion: Dose escalating a FET PET based target volume 
to above 77 Gy in 30 fractions by IMRT, VMAT, and IMPT 
without increasing both the PTV(46 Gy) homogeneity and the 
mean dose to the OAR was found feasible. For IMPT the 
PTV(46 Gy) homogeneity could be substantially reduced, 
implicating the reduction of the risk of brain necrosis despite 
the increased mean and maximum PTV boost doses. 
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Purpose or Objective: Brain metastases are a very frequent 
situation in advanced cancer and whole brain radiotherapy 
(WBRT) has long been considered the standard of care. 
Stereotactic radiosurgery has been shown to be effective in 
terms of survival and quality of life for patients with a better 
prognostic profile and a limited number (1 to 3) of brain 
metastases. More recent experiences have shown the efficacy 
of stereotactic radiation for multiple brain metastases as 
well. This may allow deferment of WBRT, in order to limit 
the risk of acute toxicity and late neurocognitive decline. 
The goal of the present study was to test from a dosimetric 
point of view a new planning software, BrainMetastases ® 
(BM) (BrainLab®, Feldkirchen - Germany), and to compare it 
with RapidArc (RA) ® plan TPS. (Varian®, Palo Alto CA, USA) 
 
Material and Methods: We retrospectively re-planned 12 
patients treated for 2 or more brain metastases in our 
institute. Median age was 53 (range 41-63). The most 
frequent number of metastases per patient was 3 (range 2-
10). The new BM software creates a dynamic arc plan 
following a simple PTV and geometrical constrains and 
calculates it with the pencil beam algorithm. For all the 
patients we studied, a plan using both BM and RA with 
different prescriptions (1x20Gy, 5x7Gy, RTOG protocol) and 
for RA plans we also considered two different plans with 6MV 
and the 10FFF beams. Finally the dosimetric parameters were 
extracted from the DVHs. 
 
Results: As PTV constraint we decided that the prescribed 
dose should cover the 90% of the PTV volume. With this 
normalization we obtained a better conformity index for RA 
plan and a smaller Healthy Brain mean dose with the BM 
plan. In particular for the patients with 3 metastases with 
6MV beam and the 5x7Gy prescription the CI99% was 1.0 1± 
0.18 and 1.56 ± 1.30 and Healthy Brain mean dose 3.0 ± 1.2 
Gy and 2.4 ± 1.1 Gy and V20Gy 13.0±6.4 cm3 and 9.6±6.5 
cm3 respectively for RA and BM technique. Also the time for 
optimization and calculation are 14.4±5.53 minutes and 
3.63±1.48 minutes. The algorithm implemented in BM is the 
pencil beam and evaluated the dose every 5° and in Eclipse is 
Acuros XB and the calculation is performed every 2°. A more 
detailed analysis concerning the OAR sparing will be 
reported. 
 
Conclusion: Plan optimisation using BM software provides a 
satisfactory dose distribution with a good conformity index 
and organs at risk sparing; the results are comparable with a 
VMAT plan. Reduction of time for optimisation and 
calculation seems to favour the BM software, with a similar 
OAR safety. Nevertheless these assumptions need to be 
balanced with the clinical experience which is currently 
ongoing in different institutes. 
 
 
 
 
